IP Library Granted Patent US 6,902,730
Granted Patent B1
US 6,902,730 · App. 09/284,180 · Granted Jun 7, 2005

Semaphorin gene: Semaphorin W

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,902,730
App. No.
09/284,180
Granted
Jun 7, 2005
Kind
B1
Abstract

The present invention provides Semaphorin W inhibiting neurite outgrowth, and a gene therefor, as well as other Semaphorins hybridizing to said Semaphorin W gene, modified proteins or partial peptides of said Semaphorin W, antibodies against said Semaphorin W, antisense nucleotides against said Semaphorin W gene, and the use of such substances as pharmaceutical or diagnostic agents or laboratory reagents. The present invention further provides a method of screening for Semaphorin W antagonists employing said Semaphorin W, Semaphorin W antagonists obtained by said screening method, pharmaceutical agents comprising such antagonists, and transgenic animals involving said Semaphorin W.

Claims (23)

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:1;

(b) the nucleotide sequence of SEQ ID NO:2; and

(c) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:3.

2. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:5; and

(b) the nucleotide sequence of SEQ ID NO:10;

wherein said polynucleotide specifically hybridizes with a complement of a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:1; and

(b) the nucleotide sequence of SEQ ID NO:2;

under conditions of a buffer comprising 45%(v/v) formamide, 5×SSPE, at 42° C., and washing after hybridization with a buffer comprising 2×SSPE at 42° C.,

and said polynucleotide encodes a protein having the biological activity of inhibiting neurite outgrowth from dorsal root ganglion cells.

3. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:5; and

(b) the nucleotide sequence of SEQ ID NO:10;

wherein said polynucleotide specifically hybridizes with a complement of a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:1; and

(b) the nucleotide sequence of SEQ ID NO:2;

under conditions of a buffer comprising 45%(v/v) formamide, 5×SSPE, at 42° C., and washing after hybridization with a buffer comprising 2×SSPE, at 42° C.;

and said polynucleotide encodes a protein having the biological activity of collapsing growth cones of retinal ganglion cells.

4. An expression plasmid comprising the nucleic acid molecule of claim 1 , 2 or 3 .

5. A host cell comprising the expression plasmid of claim 4 .

6. A process for producing a recombinant protein, comprising culturing the host cell of claim 5 under conditions sufficient for the production of said protein and recovering said protein.

Assignments (2)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 1999
From: KIMURA, TORU; KIKUCHI, KAORU
To: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Reel/Frame 010009/0070 →